Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040428 · ClinicalTrials.gov registry record · Phase 3
The Fibrin Pad CV Phase III Study
A Phase 3 study, sponsored by Ethicon.
- Completed
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
NCT02040428: Completed Phase 3 study, sponsored by Ethicon.
NCT02040428 is a Phase 3 study that has completed, run by Ethicon. The registered enrollment target is 156 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02040428, a Phase 3 study, has completed, sponsored by Ethicon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the EVARREST™ Fibrin Sealant Patch as an adjunct to hemostasis during cardiovascular surgery.
Primary Outcome
Number of subjects achieving hemostasis at the Target Bleeding Site (TBS) at 3 minutes following treatment application, with no re-bleeding at the TBS any time prior to the initiation of final chest wall closure
Interventions
- BIOLOGICAL Topical hemostat
- BIOLOGICAL EVARREST™ Fibrin Sealant Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2014-01-01 |
| Est. Completion | 2015-09-01 |
| Phase | Phase 3 |
What the finished NCT02040428 record still lists
NCT02040428 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Topical hemostat is the first listed.
NCT02040428 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02040428 about?
NCT02040428 is a clinical study titled "The Fibrin Pad CV Phase III Study". The objective of this study is to evaluate the safety and effectiveness of the EVARREST™ Fibrin Sealant Patch as an adjunct to hemostasis during cardiovascular surgery.
What is the current status of trial NCT02040428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2014-01-01. Estimated completion is 2015-09-01.
What interventions are being tested in trial NCT02040428?
The interventions under investigation include: Topical hemostat (BIOLOGICAL), EVARREST™ Fibrin Sealant Patch (BIOLOGICAL).
Who is sponsoring clinical trial NCT02040428?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02040428's enrollment target sits among peer trials
156 1506th of 2000 higher than 492 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI